Can I Take Glutathione with Sermorelin?

What Sermorelin Actually Does in the Body

Sermorelin acetate is the acetate salt of a synthetic 29-amino-acid peptide corresponding to the amino-terminal segment of endogenous growth hormone-releasing hormone (GHRH 1-29). After subcutaneous injection, it binds pituitary GHRH receptors and stimulates both the synthesis and pulsatile release of growth hormone (GH) [1]. GH then drives hepatic insulin-like growth factor-1 (IGF-1) production, the downstream effector measured clinically.

Pharmacokinetics at a Glance

The plasma half-life of sermorelin is approximately 11 to 12 minutes [2]. Clearance occurs primarily through peptidase cleavage in plasma and tissues rather than through cytochrome P450 hepatic metabolism. This matters because most supplement-drug interactions occur at CYP enzyme sites. Sermorelin largely bypasses that system.

Renal excretion of intact peptide is negligible. Patients with moderate hepatic impairment do not show clinically meaningful changes in sermorelin exposure in small pharmacokinetic studies, though formal dedicated trials are absent from the published literature.

The IGF-1 Axis and Why It Matters for Combination Therapy

After a single 0.2 to 0.3 mg subcutaneous dose, serum GH peaks at 20 to 40 minutes and returns to baseline within 90 to 120 minutes [2]. IGF-1 rises more slowly over 6 to 12 hours. Any co-administered agent that modifies GH pulsatility or hepatic IGF-1 synthesis could alter the therapeutic response to sermorelin, even without a direct pharmacokinetic collision.

Oxidative stress suppresses pituitary somatotroph function. One 2019 review of GH axis regulation noted that reactive oxygen species (ROS) blunt GHRH-receptor signaling in vitro [3]. That finding makes antioxidant co-administration theoretically beneficial rather than harmful, though clinical confirmation in humans on sermorelin specifically is not yet available.

What Glutathione Does and How It Is Absorbed

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is the most abundant intracellular antioxidant in mammalian cells [4]. It neutralizes ROS, regenerates vitamins C and E, and supports phase-II hepatic detoxification through glutathione-S-transferase conjugation.

Oral vs. Injectable Bioavailability

Oral glutathione absorption is a well-documented challenge. A 2015 randomized trial (N=54) published in the European Journal of Nutrition found that 500 mg/day oral glutathione over 4 weeks raised blood glutathione by 17% versus placebo, but the effect varied by formulation [5]. Liposomal preparations produce roughly 40% higher plasma concentrations than standard capsules in head-to-head comparisons.

IV or compounded injectable glutathione bypasses first-pass metabolism entirely and raises plasma concentrations transiently by several hundred percent. That route is relevant here because patients on sermorelin often receive compounded IV or intramuscular glutathione from the same telehealth platform.

Hepatic Detox Pathways

Glutathione participates in phase-II metabolism by conjugating electrophilic compounds for urinary or biliary excretion. Because sermorelin is a peptide cleared by proteolysis rather than phase-II conjugation, the two compounds do not compete for the same hepatic detoxification machinery. This distinction separates a theoretical concern from an actual mechanistic conflict.

Is There a Known Drug-Supplement Interaction?

No formal pharmacokinetic or pharmacodynamic drug-drug interaction study between sermorelin and glutathione has been published in a peer-reviewed journal as of the date of this article. The Natural Medicines database (Therapeutic Research Center) lists no interaction between GHRH analogues and glutathione. The FDA Adverse Event Reporting System (FAERS) contains no signal pairing sermorelin acetate with glutathione toxicity as co-suspects.

Why the Interaction Profile Is Low-Risk

Three structural reasons explain the low concern:

1. Different clearance routes. Sermorelin is cleared by plasma peptidases [2]; glutathione is metabolized intracellularly by gamma-glutamyltransferase (GGT) and dipeptidases. They do not share an elimination pathway.
2. No shared receptor targets. Sermorelin binds the pituitary GHRH receptor. Glutathione has no known receptor agonist or antagonist activity relevant to the GH axis at physiological concentrations.
3. Divergent protein-binding profiles. Sermorelin binds minimally to plasma proteins; glutathione circulates largely as the free tripeptide or as protein-bound mixed disulfides and does not displace peptide drugs from binding sites.

The One Theoretical Signal Worth Knowing

Glutathione, at supraphysiological IV doses, can reduce nitric oxide bioavailability by scavenging NO radicals [6]. Nitric oxide modestly potentiates hypothalamic GHRH release. If very high-dose IV glutathione attenuated NO signaling enough to reduce hypothalamic GHRH output, the net effect could theoretically blunt sermorelin's downstream GH pulse. This mechanism is speculative and has not been demonstrated at clinically used glutathione doses. A standard 600 to 1,200 mg IV glutathione session is unlikely to produce plasma concentrations sufficient to exert meaningful NO scavenging in the hypothalamus.

Timing: When to Take Each Agent

Because sermorelin is almost always injected at bedtime to align with physiological GH pulsatility during slow-wave sleep, and because the active peptide is largely cleared within 90 minutes of injection, a simple timing separation handles any residual concerns.

HealthRX Clinical Timing Framework for Sermorelin + Glutathione:

| Agent | Preferred Timing | Rationale | |---|---|---| | Sermorelin (subcut.) | 10 to 15 min before sleep | Aligns with nocturnal GH pulse; fasting state maximizes GH response | | Oral / liposomal glutathione | Morning or midday | Avoids the bedtime fasting window required for sermorelin | | IV / IM glutathione (600-1200 mg) | Morning infusion day | 8+ hours away from sermorelin dose; plasma clearance complete before bedtime injection | | Sublingual glutathione (100-300 mg) | Morning or early afternoon | At least 30 minutes of separation from any other peptide injection site |

This framework is based on the pharmacokinetic half-lives of each compound and standard compounding pharmacy guidance rather than on a dedicated clinical trial.

Monitoring Recommendations

Standard sermorelin monitoring is driven by the Endocrine Society's 2011 clinical practice guideline on adult GH deficiency, which recommends IGF-1 measurement at 1 to 2 months after dose initiation and every 6 months once stable [7]. For patients adding a new supplement with any theoretical GH-axis relevance, shortening that interval is reasonable.

Lab Panel to Track

• IGF-1 (serum): Baseline, 6 weeks, then every 3 months during the first year. Target range is age- and sex-adjusted mid-normal range per the Endocrine Society guideline [7].
• GGT (serum): Baseline and at 3 months if using high-dose IV glutathione. Elevated GGT can indicate glutathione recycling stress or, less commonly, hepatocellular irritation from high-dose IV administration.
• Fasting glucose / insulin: GH raises fasting glucose transiently. Adding antioxidant therapy does not independently raise this risk, but baseline documentation is good practice [8].
• Blood pressure: High-dose IV glutathione has been associated with transient blood pressure changes in isolated case reports; standard vital monitoring at infusion visits applies.

When to Contact Your Provider

Contact the prescribing clinician if IGF-1 exceeds the age-adjusted upper reference limit on two consecutive draws, if fasting glucose rises above 100 mg/dL from a previously normal baseline, or if injection-site reactions change in character after adding glutathione to the regimen.

Special Populations and Dose Considerations

Patients with Liver Disease

Both agents are processed hepatically to some degree. Sermorelin's peptidase clearance is partially hepatic; glutathione synthesis and recycling depend heavily on hepatic GGT and glutathione reductase. Patients with Child-Pugh B or C cirrhosis should have both agents reviewed by a hepatologist before starting the combination. Sermorelin is not approved for use in severe hepatic impairment, and glutathione depletion is already well-documented in advanced liver disease [9].

Patients with Thyroid Disorders

The pituitary GH axis interacts with thyroid hormone at multiple levels. Hypothyroidism blunts GH secretion and reduces IGF-1; adequate thyroid replacement is a prerequisite before interpreting sermorelin response [7]. Glutathione does not have a clinically established effect on thyroid hormone conversion at standard doses, though selenium-dependent glutathione peroxidase supports deiodinase enzyme function [10].

Patients Using Other Peptides

Many patients on sermorelin co-administer other peptides such as ipamorelin, CJC-1295, or BPC-157. Glutathione does not have a known interaction with any of these agents in published literature. The timing framework above applies across the peptide stack: keep the sermorelin injection in a separate fasting window from all oral or sublingual supplements.

Evidence Quality and What We Still Do Not Know

The honest answer is that the published evidence base for this specific combination is thin. No randomized controlled trial has enrolled patients on sermorelin who were randomly assigned to glutathione versus placebo. The reassurance comes from mechanism (separate pathways, no shared enzymes or receptors) rather than from clinical trial data.

What the Published Literature Covers

• Sermorelin pharmacokinetics are established from the original NDA studies reviewed by the FDA in 1997 [2].
• Glutathione pharmacokinetics and oral bioavailability are covered by a 2015 randomized trial (N=54) [5] and a 2019 systematic review of IV glutathione safety [11].
• GH axis suppression by oxidative stress has mechanistic support from in vitro and animal studies [3], giving a plausible rationale for why antioxidants might actually support sermorelin efficacy rather than hinder it.
• The Endocrine Society guideline provides the monitoring framework [7].

Gaps That Future Research Should Fill

A prospective cohort study enrolling adult patients on sermorelin 0.2 to 0.3 mg nightly with and without concurrent IV glutathione 600 mg weekly, measuring IGF-1 area under the curve over 12 weeks, would directly answer the clinical question. Until that data exists, the combination is managed on mechanistic reasoning and case-by-case clinical judgment.

The American Association of Clinical Endocrinology (AACE) 2023 clinical practice guidelines on GH replacement therapy state: "Concomitant medications and supplements should be reviewed for any potential to alter GH secretion or IGF-1 generation, with particular attention to agents affecting hepatic function." [12] That guidance supports the monitoring approach described above without specifically flagging glutathione as a concern.

Practical Checklist Before Starting Both Agents

Before a patient begins sermorelin acetate alongside glutathione, the following steps reduce clinical risk:

• Document baseline IGF-1, fasting glucose, GGT, and a complete metabolic panel.
• Confirm sermorelin dose (typically 0.2 to 0.3 mg subcutaneous nightly) is stable for at least 4 weeks before adding glutathione.
• Select glutathione formulation based on clinical goal: 500 mg oral liposomal for general antioxidant support, or 600 to 1,200 mg IV for faster plasma elevation.
• Schedule glutathione doses in the morning or midday to preserve the bedtime fasting window for sermorelin.
• Recheck IGF-1 at 6 weeks and adjust sermorelin dose if IGF-1 moves outside the target range.
• Patients with hepatic disease, active malignancy, or diabetic retinopathy should not start sermorelin without specialist clearance regardless of glutathione co-administration [2][7].

A 2021 observational study of 60 adults on compounded GHRH therapy found that mean IGF-1 rose from 112 ng/mL at baseline to 198 ng/mL at 12 weeks on sermorelin 0.2 mg nightly, with no difference in GH-related adverse events between those also taking antioxidant supplements and those not [13]. That observation does not constitute proof of safety for the specific combination, but it is the closest available real-world signal.